Overview
The Supreme Court heard oral argument this week in Hikma v. Amarin (Case No. 24-889), a patent case addressing whether generic drugmakers can face secondary liability for actively inducing infringement under 35 U.S.C. § 271(b). Specifically, the Court is considering whether a patent owner can state a claim for induced infringement if a generic drugmaker labels its product identically to the brand-name drug, while carving out patented uses for the drug (a so-called “skinny label”) but markets its product as the “generic version” of the brand-name drug. This argument follows shortly on the heels of the Supreme Court’s recent decision in Sony v. Cox, which held that “a company is not liable as a copyright infringer for merely providing a service to the general public with knowledge that it will be used by some to infringe copyrights.”
While it is always risky to read too much into oral argument, the Court did seem to suggest that some of the concern surrounding the case may be overstated. Rather than treating the dispute as an occasion to reshape Hatch‑Waxman doctrine or impose new affirmative obligations on generic manufacturers, much of the argument focused on familiar ground: whether the complaint alleges facts that state a plausible claim for inducement under the well-known standard set by Twombly and Iqbal. Consistent with that framing, both sides acknowledged an important baseline point—that there is no requirement that a generic drugmaker affirmatively disclaim patented indications on its skinny label. That shared premise cuts against broader fears that regulatory‑compliant labeling alone now carries heightened inducement risk.
The more consequential debate centered on what circumstantial evidence could support a plausible inference that a drugmaker intended to induce infringement. That question becomes a challenge, if the defendant’s conduct can be interpreted as being consistent with lawful, non‑infringing behavior (e.g., marketing the generic for only the non-patented uses for which it is approved). The argument repeatedly returned to modern copyright decisions involving online piracy, MGM v. Grokster and Sony v. Cox, and to the distinction between active encouragement of infringement versus passive awareness that infringement may occur (or even that it likely would). The Court seemed to have little appetite for collapsing that distinction.
At the same time, the Court appeared interested in how intent can be inferred from context or conduct, including statements that may be true on their face or drawn from third‑party sources, but which take on different significance when viewed as part of a broader course of conduct. That inquiry takes on added importance here, given the unusual procedural posture: the case proceeded into discovery after the Federal Circuit reversed dismissal, prompting arguments that new evidence may now bear on intent. While the Court seemed reluctant to resolve those procedural questions itself, the discussion suggests that any decision may leave useful guidance on what kinds of allegations, and what kinds of circumstantial facts, can plausibly support a claim of inducement at the pleading stage. If so, the case may ultimately be remembered less as a referendum on skinny labels than as a refinement of how courts evaluate intent under § 271(b) when lawful conduct and alleged inducement sit uncomfortably close together.
